title: Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion.
authors: Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey.
authors: Hakan
authors: H
authors: Kocoglu
authors: Mustafa
authors: M
authors: Karaca
authors: Rustu
authors: R
authors: Turkay
authors: Deniz
authors: D
authors: Tural
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D002830:Choroid Neoplasms / Q000556:secondary*; D002872:Chromosome Deletion; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use*; D005091:Exons; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged
chemical_list: D000970:Antineoplastic Agents; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors